In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00…
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at…
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica®…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company specializing in genetic diseases and cancers, unveiled findings from the exploratory CMR imaging substudy of its Phase 3 trial, ATTRibute-CM, evaluating…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome…
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the…
Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive…
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients…
ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter…
Updated findings on overall survival (OS) from a planned evaluation, encompassing around 75% of data, reveal an OS hazard ratio below 1.0 (HR<1.0) within the intent-to-treat (ITT) population, not adjusted…